Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gilenya Modifying Therapy for MS”

4 trials

Showing 4 of 4 results

Not applicableStudy completedNCT02141022
What this trial is testing

Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya

Who this might be right for
Multiple SclerosisCognitive DeficitsGilenya Modifying Therapy for MS
Stony Brook University 20
Post-approval studies (Phase 4)Study completedNCT01534182
What this trial is testing

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Novartis Pharmaceuticals 298
Post-approval studies (Phase 4)Study completedNCT01216072
What this trial is testing

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Relapsing Forms of Multiple Sclerosis
Novartis Pharmaceuticals 1,053
Post-approval studies (Phase 4)Study completedNCT01317004
What this trial is testing

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Novartis Pharmaceuticals 61

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation